CONTROL STUDY OF THALIDOMIDE (KEVADON), A NEW HYPNOTIC AGENT
Abstract
1. Kevadon, in short term hypnotic effect, is equal to, if not more adequate than, phenobarbital; 2. It seems—and this has to be confirmed with more detailed studies—that Kevadon has less after or "hang over" effect than phenobarbital; 3. It seems to be difficult to produce a prolonged state of sleep with Kevadon; 4. If further control trials substantiate these conclusions, Kevadon will become a valuable hypnotic substance.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).